With the increased frequency of diagnostic imaging, pancreatic cysts are now detected in >3% of American adults. Most of these are intraductal papillary mucinous neoplasm (IPMN) with well-established but variable malignant potential. A biomarker that predicts malignant potential or dysplastic grade would help determine which IPMN require removal or can be safely observed. We previously reported that pancreatic fluid prostaglandin E 2 (PGE 2 ) levels may have promise as a predictor of IPMN dysplasia and seek to validate these results in the current study. Study Design: Pancreatic cyst/duct fluid was prospectively collected from 100 patients with IPMN undergoing pancreatic resection. Surgical pathology revealed 47 low/moderate grade, 34 high grade, and 20 invasive IPMN. PGE 2 levels were assessed by enzyme-linked immunoassay and correlated with IPMN dysplasia grade, demographics, clinical radiologic/pathologic variables, acute/chronic pancreatitis and non-steroidal anti-inflammatory drug use. Results: Mean pancreatic cyst fluid PGE 2 levels in high grade and invasive IPMN were significantly higher than low/moderate grade IPMN (3.5 and 4.4 respectively versus 1.2pg/µl, p<0.0016). At a threshold of 1.1pg/µl, PGE 2 was 63% sensitive, 79% specific, and 71% accurate for detection of high grade/invasive IPMN. When tested in the subset of IPMN patients with preoperative pancreatic cyst fluid CEA >192ng/mL, PGE 2 at a threshold of 0.5pg/µl demonstrated 78% sensitivity and 100% specificity, and 86% accuracy for detection of high grade/invasive IPMN. M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 4 Conclusions: Our results validate pancreatic cyst fluid PGE 2 as an indicator of IPMN dysplasia especially in select patients with preoperative pancreatic cyst fluid CEA >192ng/mL. The inclusion of PGE2/CEA in a diagnostic biomarker panel may facilitate more optimal treatment stratification of IPMN patients.
Pancreatic cancer will be diagnosed in an estimated 53,070 Americans this year. In 2016, 41,780 died from pancreatic cancer. This makes pancreatic cancer the third leading cause of cancer-related death in the United States surpassing mortality from breast cancer (1) . The aggressive biology and typical late discovery of pancreatic cancer contribute to these statistics (1) . Most patients have inoperable disease and no chance for cure at the time of presentation (2) . Thus, there is an urgent need for both improved systemic treatment options and earlier diagnostic strategies. Early detection and prevention of pancreatic cancer may be the answer for a unique subset of high-risk patients. Cystic lesions of the pancreas, some of which may progress to pancreatic cancer, provide the clinician with an opportunity to intervene prior to malignant transformation. While non-discriminatory resection of all pancreatic cysts would prevent many cancer cases, an unacceptable number of patients with low malignant potential pancreatic cysts would undergo unnecessary, potentially morbid pancreatic resection. Accurate preoperative diagnosis of pancreatic cyst type and malignant potential is therefore of utmost importance for optimal surgical risk stratification.
Intraductal papillary mucinous neoplasm (IPMN) is the most common premalignant mucinous cystic lesion of the pancreas. Most IPMN are accurately diagnosed based on radiographic features of multifocal ductal dilation alone. Unifocal (solitary) IPMN, however, must be distinguished from mucinous cystic neoplasm (MCN). MCN may be diagnosed by the presence of ovarian stroma on core biopsy or EUS-directed micro forceps biopsy. Unifocal Clinical management of IPMN, once diagnosed, is guided by an assessment of malignant potential. A fine needle aspiration consistent with high grade atypia or a core biopsy or EUSdirected micro-forceps biopsy consistent with high grade dysplastic or invasive IPMN may occasionally be available. An accurate dysplastic grade, however, is usually not known prior to IPMN surgical resection. Malignant potential of IPMN is linked to type of pancreatic ductal involvement. IPMN with branch-duct involvement alone (branch type) may often be observed while IPMN with main-duct involvement (with or without branch-duct involvement, i.e., mixed type and main type) are usually recommended for resection due to a higher risk of malignant transformation (4) . Preoperative differentiation of IPMN ductal involvement is guided by crosssectional imaging and endoscopic modalities. Nearly 30% of IPMN cases, however, are misclassified as having main duct involvement preoperatively that do not on surgical pathology (5) . Conversely, 20% of IPMN thought to have branch-duct involvement alone preoperatively have main duct involvement on surgical pathology (5) .
Although branch duct versus main duct differentiation is an important distinction in assessing IPMN malignant risk, it is unreliable by itself. There are a number of clinical factors and imaging characteristics which may be useful in prediction of IPMN malignant potential, including age, symptoms/signs/conditions, imaging, cytology, DNA profiling, labs, family history, obesity(6), smoking (7) , new onset diabetes (8) , main duct size, and presence of mural nodules(4). However, no existing preoperative predictive factors are accurate enough to identify high-risk IPMN for surgical removal and/or low-risk IPMN that can be safely monitored. Highly accurate preoperative biomarkers are necessary to optimize preoperative risk stratification.
Prostaglandin E 2 (PGE 2 ) is a product of cyclooxygenase-2 (COX-2), a key enzyme in the inflammatory pathway (9) . COX-2 overexpression and elevated PGE 2 levels have been observed in multiple cancer types including pancreas (10) (11) (12) (13) . We previously reported that pancreatic cyst fluid PGE 2 levels correlated with degree of IPMN dysplasia in a small cohort of IPMN patients (n=29) (14) . In the present study, we aim to validate these findings with a larger cohort to evaluate the diagnostic utility of PGE 2 as a biomarker for high risk IPMN.
Methods:
Pancreatic 
Statistical Analysis
IBM Statistical Package for the Social Sciences (SPSS) 24 was used for all statistical analyses. Graphpad Prism 7.02 was used for graphical representation of data. Descriptive statistics including mean, standard deviation, and frequencies were calculated as appropriate.
Baseline demographic and clinic-pathologic data were compared between low/moderate grade dysplasia (LGD/MGD) and high-grade dysplasia (HGD)/invasive IPMN using t test for continuous data and chi square for categorical data. Groups were further subdivided into
LGD/MGD, HGD, and invasive IPMN and compared using ANOVA and chi square. Pearson
correlation coefficient was calculated for determination of PGE 2 association with other continuous variables. PGE 2 was then analyzed based on each additional categorical demographic/clinicopathologic variable using t test and ANOVA. Univariate and multivariate analyses were conducted to compare PGE 2 levels between IPMN dysplasia grades. P-values of <0.05 were considered statistically significant. The diagnostic utility of PGE 2 as a biomarker for HGD/invasive IPMN was ascertained using sensitivity/specificity calculations and receiver operator characteristic analyses.
Results:
A cohort of 100 patients preoperatively diagnosed with IPMN consented to participation in the study. Following pancreatic resection and subsequent pathological confirmation of IPMN, After excluding patients with non-diagnostic cytology results, sensitivity was 23%, specificity was 89%, and accuracy was 58% for the identification of high grade/invasive IPMN by cytology (n=65). In the cytology cohort with cyst fluid CEA >192 ng/mL (n=27), sensitivity, specificity, and accuracy were 38%, 73%, and 52% respectively.
Discussion:
For patients with pancreatic IPMN, an accurate assessment of malignant potential is critical to guide optimal clinical care. The gold standard for determination of malignant potential is dysplastic grade assessed on pathology. Few IPMN are feasible for core biopsy or EUSdirected micro-forceps biopsy with adequate sampling for dysplastic grade assessment. In the current series, no core biopsies were performed. EUS-directed fine-needle-aspiration is routine in larger IPMN but the resultant cytology is often inaccurate or non-diagnostic for IPMN dysplasia (53% in the current series). Other markers of malignant potential including demographic, clinical, laboratory, endoscopic, and radiographic parameters fall short of an accurate prediction of dysplastic grade. Thus, a significant challenge persists in preoperative determination of IPMN Newer pancreatic cyst fluid biomarkers are more commonly sufficient to distinguish cyst types. None, however, has consistently been a reliable indicator of IPMN dysplasia (15) . Perhaps the most widely used pancreatic cyst fluid biomarker is CEA (16) . CEA is able to differentiate mucinous from non-mucinous type cysts with an accuracy of 77% according to a large multiinstitutional validation study of 1,861 patients (17) . However, CEA alone lacks sufficient accuracy for routine identification of mucinous cysts and does not correlate with grade of dysplasia (18) (19) (20) . A DNA mutation in KRAS is sufficient to diagnose mucinous cystic lesions (IPMN and MCN). A GNAS mutation is sufficient to diagnose IPMN and distinguish it from MCN and other non-mucinous pancreatic cyst types (21, 22) . Neither the presence of KRAS, GNAS, or both mutations predict malignancy (18, 23) . PancraGEN is a commercially available test that measures quantity and quality of DNA, KRAS, and GNAS oncogene mutations, LOH tumor suppressor mutations and DNA mutation copy number. Based on a proprietary combination of this molecular data and clinical variables, PancraGEN categorizes a pancreatic cyst as benign, statistically indolent, statistically higher risk, or aggressive (24) . These categories guide a clinician's recommendations for surveillance or surgery. This test is expensive but reports a higher accuracy than the 2012 algorithm as put forward by the revised International Consensus Guidelines. It too falls short of an optimal test to predict malignant potential.
We previously reported that pancreatic fluid prostaglandin E 2 (PGE 2 ) may be a promising biomarker of IPMN dysplasia (14) . The present study seeks to validate this in a larger cohort of Importantly, when evaluated in a population of patients with CEA >192ng/mL, the accepted cutoff for mucinous versus non-mucinous cyst differentiation, diagnostic accuracy increased to 86% with 78% sensitivity and 100% specificity. This demonstrates that when utilized in a subset of patients with higher CEA production, the diagnostic accuracy of PGE 2 as a biomarker of IPMN dysplasia substantially improves. Why a higher CEA would identify a subset of IPMN patients where PGE 2 , a marker of inflammation, would be more predictive is unclear. Finally, while cyst fluid PGE 2 levels in other pancreatic cysts such serous cystadenomas (SCN) and MCN are low as in LGD/MGD IPMNs, PGE 2 levels in a small number of pseudocysts tested in our laboratory were relatively high (unpublished observations). Thus, PGE2 would be most useful specifically in patients with pre-operative diagnosis of IPMN as a predictor of IPMN dysplasia.
The observed stepwise increase in mean PGE 2 levels with IPMN dysplastic grade suggests that PGE2 production may be associated with malignant progression. To further evaluate this, a prospective study testing serial samples from individual patients under surveillance for possible IPMN should be performed. PGE 2 is known to be involved in both angiogenesis and immunosuppression in the tumor microenvironment thus facilitating tumorigenesis (25) . We have previously shown that the PGE 2 pathway plays an important role in pancreatic tumorigenesis. Specifically, we demonstrated that COX-2, one of the enzymes that catalyzes the reaction producing prostaglandins, is over-expressed in precursor lesions known as pancreatic intraepithelial neoplasias (PanINs) and pancreatic adenocarcinomas (10, 11) .
M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT 14 Furthermore, NSAIDs that inhibit COX activity and block the inflammatory response may inhibit tumor growth in combination with other agents both in cell culture and animal models, including developmental models, of pancreatic cancer (10, (26) (27) (28) .
Limitations of the current study include being retrospective with the majority of samples originating from a single institution. Validation of these results in a large, prospective multiinstitution study would be optimal. Additionally, all patients included in this study underwent surgical resection and therefore may not be representative of the population overall population of surveillance and surgical patients in whom PGE 2 testing would potentially be useful.
Other potential cyst fluid biomarkers for the determination of IPMN dysplasia have been reported in the literature. The cytokine interleukin-1β (IL1β) was shown to be 92% accurate in detecting HGD/invasive IPMN in a sample size of 40 cyst fluids (29) . This report of IL1 and ours of PGE 2 , both markers of inflammation elevated in high-risk IMPN, provide evidence for the involvement of inflammation with malignant progression -either as a cause or consequence.
Regardless, such immune response indicators may serve as potential biomarkers of dysplasia and warrant further testing. Telomerase activity has also been recently reported to be higher in invasive than non-invasive mucinous lesions with an accuracy of 88.2% in the identification of HGD/invasive IPMN (30, 31) . Several microRNA (miRNA)-based biomarkers have shown promise in detecting high-risk IPMN (32, 33) . Matthaei (36) . One or more of these markers may fulfill the clinical need for a marker of IPMN dysplasia, but all await more extensive validation.
Conclusions
We have validated PGE 2 
